Medications

Novartis profit slips as key drug goes generic

Swiss drug company Novartis saw net profit slip in the third quarter as the loss of a key drug to generic use in the United States outweighed strong sales of its psoriasis drug Cosentyx and MS treatment Gilenya.

Medications

Lawmakers demand answers on leukemia drug price hikes

Two top lawmakers on Thursday demanded information from a drug company that has raised prices on a leukemia drug, calling increases of tens of thousands of dollars a sign the company puts profits before patients.

Oncology & Cancer

Excess relative risk of repeat CT scans can be quantified

(HealthDay)—Excess relative risk of computed tomography (CT) scans for quantification of cystic fibrosis (CF) can be calculated, according to a letter published in the Dec. 1 issue of the American Journal of Respiratory ...

Oncology & Cancer

Gleevec's latest approval is for pediatric cancer

(HealthDay)—The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat the most common type of pediatric cancer, affecting some 2,900 children each year, the agency said ...

Medications

NGOs protest Novartis' Glivec patent quest in India

Several NGOs protested Thursday at the annual meeting of Novartis against the attempt by the Swiss pharmaceutical group's India company to obtain a patent for its anti-cancer drug Glivec.

Oncology & Cancer

Study of two sisters sheds light on lymphoma evolution

When a 41-year-old woman was diagnosed with chronic-phase chronic myeloid leukemia, she received a bone marrow transplant and subsequent leukocyte infusion from her sister. These treatments controlled her leukemia, but seven ...

page 9 from 10